Jpmorgan Chase & CO Janux Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 135,308 shares of JANX stock, worth $3.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

135,308

Previous 191,603 29.38%

Holding current value

$3.22 Million

Previous $10.3 Million 64.39%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$27.0 - $57.81 $1.52 Million - $3.25 Million	-56,295 Reduced 29.38%	135,308 $3.65 Million
Q4 2024 Feb 12, 2025	BUY	$40.18 - $66.83 $6.96 Million - $11.6 Million	173,211 Added 941.77%	191,603 $10.3 Million
Q3 2024 Dec 26, 2024	SELL	$35.29 - $50.26 $28,973 - $41,263	-821 Reduced 4.27%	18,392 $835,000
Q3 2024 Nov 08, 2024	SELL	$35.29 - $50.26 $28,973 - $41,263	-821 Reduced 4.27%	18,392 $835,000
Q2 2024 Dec 26, 2024	BUY	$35.12 - $64.78 $28,833 - $53,184	821 Added 4.46%	19,213 $804,000
Q2 2024 Aug 12, 2024	SELL	$35.12 - $64.78 $4,565 - $8,421	-130 Reduced 0.67%	19,213 $804,000
Q1 2024 Dec 26, 2024	BUY	$7.93 - $49.75 $7,541 - $47,312	951 Added 5.17%	19,343 $728,000
Q1 2024 May 10, 2024	BUY	$7.93 - $49.75 $12,743 - $79,948	1,607 Added 9.06%	19,343 $728,000
Q4 2023 Dec 26, 2024	SELL	$5.85 - $11.7 $3,837 - $7,675	-656 Reduced 3.57%	17,736 $190,000
Q4 2023 Feb 12, 2024	SELL	$5.85 - $11.7 $765,607 - $1.53 Million	-130,873 Reduced 88.07%	17,736 $190,000
Q3 2023 Nov 14, 2023	SELL	$9.56 - $14.0 $46,146 - $67,578	-4,827 Reduced 3.15%	148,609 $1.5 Million
Q2 2023 Aug 11, 2023	BUY	$11.08 - $15.92 $263,471 - $378,561	23,779 Added 18.34%	153,436 $1.82 Million
Q1 2023 May 18, 2023	BUY	$11.25 - $22.21 $147,892 - $291,972	13,146 Added 11.28%	129,657 $1.57 Million
Q1 2023 May 11, 2023	BUY	$11.25 - $22.21 $143,190 - $282,688	12,728 Added 12.26%	116,511 $1.41 Million
Q4 2022 Feb 13, 2023	SELL	$11.1 - $18.26 $14,097 - $23,190	-1,270 Reduced 1.21%	103,783 $1.37 Million
Q3 2022 Nov 14, 2022	BUY	$10.82 - $16.84 $17,041 - $26,523	1,575 Added 1.52%	105,053 $1.42 Million
Q2 2022 Aug 11, 2022	BUY	$9.52 - $15.65 $814,455 - $1.34 Million	85,552 Added 477.25%	103,478 $1.26 Million
Q1 2022 May 11, 2022	BUY	$13.24 - $20.24 $61,407 - $93,873	4,638 Added 34.9%	17,926 $256,000
Q4 2021 Feb 10, 2022	BUY	$15.44 - $27.32 $105,208 - $186,158	6,814 Added 105.25%	13,288 $262,000
Q3 2021 Nov 12, 2021	BUY	$20.7 - $34.69 $134,011 - $224,583	6,474 New	6,474 $140,000

Others Institutions Holding JANX

# of Institutions

193

Shares Held

57.3M

Call Options Held

626K

Put Options Held

155K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $992M
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Janux Therapeutics, Inc. Transaction History